Gilead Sciences

Vertex Pharmaceuticals

Amgen

Regeneron Pharmaceuticals

Alnylam Pharmaceuticals

Biogen

Illumina

United Therapeutics

Viatris

Moderna

Invesco Nasdaq Biotechnology ETF

IBBQ tracks a modified market-cap-weighted index of US biotechnology and pharmaceutical companies listed on the NASDAQ.

IBBQ is a relatively new U.S. biotech ETF that competes with established peers like IBB and XBI. IBBQ has outperformed both since its June 2021 launch date. However, there are specific risks investors should consider first. In addition to the volatile nature of the biotech industry, I'll review IBBQ's liquidity, concentration, and quality features in detail. IBBQ also has a high liquidation risk. With only $38 million in assets under management and a 0.19% expense ratio, IBBQ likely isn't a profitable product for Invesco.

IBBQ: This Low-Cost Biotech ETF Comes With Unique Risks

Following a multiyear run of disappointment, biotech stocks and related ETFs are showing signs of life. For the past 90 days ending February 29, the widely observed Nasdaq Biotechnology Index was higher by almost 17%.

Biotech Rally in Its Early Innings

Invesco DWA Healthcare Momentum ETF

Invesco S&P 500 Equal Weight Technology ETF

VanEck Vectors Semiconductor ETF

Consumer Discretionary Select Sector SPDR Fund

The Nasdaq Composite and the S&P 500 hit new all-time high Friday. However, there are chances of further rally.

6 Factors to Bet on Wall Street: ETFs to Buy

VanEck Vectors Biotech ETF

Virtus LifeSci Biotech Products ETF

Bristol-Myers

iShares Nasdaq Biotechnology ETF

Johnson & Johnson

Merck

SPDR S&P Biotech ETF

The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-time.

Biotech ETFs Stage Solid Comeback at the Start of 2024

JPMorgan BetaBuilders U.S. Small Cap Equity ETF

 Invesco S&P SmallCap Consumer Discretionary ETF

Vanguard S&P Small-Cap 600 Value ETF

WisdomTree Cloud Computing Fund

SPDR S&P Retail ETF

SPDR S&P Semiconductor ETF

Wall Street witnessed an upbeat December due to moderation in inflationary pressures, the likelihood of Fed rate cuts in 2024 and decent corporate earnings.

5 Top-Ranked ETF Winners of December With More Room for Gains

Invesco Dynamic Pharmaceuticals ETF

Bank of America expects the Gilead Sciences to jump about 30%, as quoted on CNBC.

Time for Gilead Sciences-Heavy ETFs?

First Trust Morningstar Dividend Leaders Index Fund

First Trust Nasdaq Pharmaceuticals ETF 

Amplify Treatments Testing & Advancements ETF

iShares Core High Dividend ETF

Horizon Kinetics Medical ETF

Novavax

Pfizer

The FDA advised to Pfizer, Moderna and Novavax to manufacture single-strain jabs targeting the omicron subvariant XBB.1.5 should prove to be a victory for some biotech ETFs.

Biotech ETFs in Focus on Covid Vaccines' Fall Rollout

Simplify Health Care ETF

Sanofi

Shares of drugmakers Sanofi and Regeneron surged more than 6% on Mar 23 on COPD drug data.

ETFs in Focus on Sanofi and Regeneron's COPD Drug Data

Global X Longevity Thematic ETF 

ARK Genomic Revolution Multi-Sector ETF

Virtus LifeSci Biotech Clinical Trials ETF

BlackRock Future Health ETF

Principal Healthcare Innovators Index ETF

Loncar Cancer Immunotherapy ETF

Global X Telemedicine & Digital Health ETF

First Trust NYSE Arca Biotechnology Index Fund

Fidelity MSCI Health Care ETF

First Trust Health Care AlphaDEX Fund

Global X Genomics & Biotechnology ETF

 Franklin Genomic Advancements ETF

ROBO Global Healthcare Technology and Innovation ETF

iShares Genomics Immunology and Healthcare ETF

iShares U.S. Pharmaceuticals ETF

iShares U.S. Healthcare Providers ETF

iShares U.S. Medical Devices ETF

iShares Global Healthcare ETF

iShares U.S. Healthcare ETF

Eli Lilly

Global X Longevity Thematic ETF

First Trust Indxx Medical Devices ETF

Novo Nordisk

Invesco Dynamic Biotechnology & Genome ETF

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

VanEck Vectors Pharmaceutical ETF

Invesco S&P SmallCap Health Care ETF

Invesco S&P 500 Equal Weight Health Care ETF

ALPS Medical Breakthroughs ETF

Vanguard Health Care ETF

Wisdomtree BioRevolution Fund

SPDR S&P Health Care Equipment ETF

SPDR S&P Health Care Services ETF

Health Care Select Sector SPDR Fund

SPDR S&P Pharmaceuticals ETF

How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.

Can Health Care Stocks Outperform Again In 2023?

The pharmaceuticals/biotechnology subsector has good value and quality scores. The healthcare equipment industry is significantly overvalued.

IBBQ: Healthcare Dashboard For December

ProShares Ultra Nasdaq Biotechnology

iShares Neuroscience And Healthcare ETF

Recognition that aging populations will give rise to new healthcare needs and heightened awareness of mental health issues are bringing renewed focus to neurological health. Recent advances in genomics and immunology, new diagnostics and surgeries, and reductions in stigma associated with mental health are unlocking radical progress in neuroscience this decade akin to the genomics revolution of the past two decades.

Why Now Could Be The Time To Consider Neuroscience Investments

Biotech has had a strong rally since June, when fortune for the sector abruptly pivoted after months of underperformance.   The sector peaked in early 2021 but struggled to continue the momentum, despite numerous tailwinds for the space.

Invesco's Rene Reyna on Biotech's Rally and the Potential for Future Growth

Moderna Inc (NasdaqGS: MRNA) shares surged Wednesday, lifting biotechnology sector-related exchange traded funds, after the pharmaceutical company revealed better-than-expected profit and revenue in its latest quarterly report, along with a share buyback plan. On Wednesday, the Invesco Nasdaq Biotechnology ETF (IBBQ) increased 4.2%, the ETFMG Treatments Testing and Advancements ETF (GERM) advanced 5.

Moderna Q2 Earnings, Buyback Plans Lift Biotech ETFs

iShares Evolved U.S. Innovative Healthcare ETF

Pharma and biotech ETFs are in great shape and are trading at a one-month high level.

Pharma & Biotech ETFs at One-Month High: Here's Why

Earlier this week, Pfizer (NYSE:PFE) announced plans to acquire Biohaven Pharmaceutical (NASDAQ:BHVN) for $11.6 billion, sparking hopes of more biotechnology consolidation activity to come. Pfizer is paying a 33% premium for the maker of Nurtec ODT, a well-known migraine headache treatment.

Pfizer Biohaven Acquisition Sparks Hope of More Biotech M&A

After disappointing in 2021, biotechnology stocks and exchange traded funds are getting shellacked this year as growth stocks fall out of favor due to rising interest rates. As experienced biotech investors know, the industry frequently trades at premiums relative to the broader market, and extreme discounts are rare.

Battered Biotech Space Now Unbelievably Inexpensive

Biotechnology sector-specific exchange traded funds were flat after Amgen (NasdaqGS: AMGN) provided a mixed earnings report but announced that it will return value to investors through greater share buybacks. On Tuesday, the Invesco Nasdaq Biotechnology ETF (IBBQ) was down 0.1%, the iShares Biotechnology ETF (IBB) fell 0.1%, and the VanEck Vectors Biotech ETF (BBH) was unchanged.

Biotech ETFs Muddled Despite Amgen Strength

ProShares UltraShort Nasdaq Biotechnology

The biotechnology industry is a bifurcated space. In one corner, you have nascent, small-cap companies that don't yet have steady revenue streams because their new drug or treatment is still in development, hasn't received FDA approval, or hasn't been in the market long enough to establish a proven track record.

Cap-Weighting Crucial When Indexing Biotech

Although biotechnology stocks have been lackluster for the past year, the industry is gaining increased attention of late, not just for the role it's played in combatting the COVID-19 pandemic, but also for the headlines that several biotech firms have made in accelerating methods to diagnose and treat cancer. Some key players in the industry [.

Biotech Firms Partner to Advance Therapeutic Medicine

Innovative biotechnology companies are coming out with novel treatments in the healthcare industry. Investors can also capture the ongoing innovations in the biotech sector through a targeted exchange traded fund that tracks the benchmark Nasdaq Biotechnology Index.

An ETF to Capture Promising Biotech Innovators

As is now widely documented, biotechnology stocks and exchange traded funds endured a rough 2021. Compounding those woes is the fact that investors were caught off guard by last year's lethargy because biotechnology assets surged in 2020.

Biotech Stocks and ETFs Can Get Their Grooves Back

The biotechnology industry is often a hotbed of mergers and acquisitions speculation. Announced deals are a different matter altogether.

Expect More Biotech Consolidation Activity in 2022

Moderna (NasdaqGS: MRNA) jumped on Monday after announcing that a higher dosage booster of its vaccine could help mitigate COVID-19 Omicron risks before a tailor-made shot is finalized, lifting biotechnology sector-related exchange traded funds. On Monday, the Invesco Nasdaq Biotechnology ETF (IBBQ) rose 1.4% and iShares Biotechnology ETF (IBB) gained 1.7%.

Moderna's Omicron Booster Strategy Lifts Biotechnology ETFs

Broadly speaking, 2021 hasn't been kind to biotechnology stocks and exchange traded funds, but some market participants remain optimistic regarding a rebound for these previously beloved assets. One way investors can position for such an event is to lean toward higher quality, less speculative, large-cap biotech names.

Position for Biotech Rebound With Quality Names

While Covid-19 variants on the rise, the push for more vaccinations make the Invesco Nasdaq Biotechnology ETF (IBBQ) an ETF to watch. As Covid cases experience a resurgence, more companies are mandating workers get vaccinated.

News for Invesco Nasdaq Biotechnology ETF ETF (IBBQ)